TG Therapeutics, Inc. (TGTX)
55.98
-0.72
(-1.28%)
USD |
NASDAQ |
Sep 04, 16:00
56.00
+0.02
(+0.03%)
After-Hours: 20:00
TG Therapeutics Research and Development Expense (Quarterly) : 95.34M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 95.34M |
| March 31, 2026 | 48.40M |
| December 31, 2025 | 41.19M |
| September 30, 2025 | 40.88M |
| June 30, 2025 | 31.78M |
| March 31, 2025 | 46.36M |
| December 31, 2024 | 23.87M |
| September 30, 2024 | 20.14M |
| June 30, 2024 | 17.56M |
| March 31, 2024 | 32.72M |
| December 31, 2023 | 17.45M |
| September 30, 2023 | 14.75M |
| June 30, 2023 | 28.12M |
| March 31, 2023 | 15.87M |
| December 31, 2022 | 29.64M |
| September 30, 2022 | 20.80M |
| June 30, 2022 | 26.87M |
| March 31, 2022 | 48.04M |
| December 31, 2021 | 62.65M |
| September 30, 2021 | 51.97M |
| June 30, 2021 | 44.87M |
| March 31, 2021 | 63.09M |
| December 31, 2020 | 42.96M |
| September 30, 2020 | 50.46M |
| June 30, 2020 | 36.45M |
| Date | Value |
|---|---|
| March 31, 2020 | 36.02M |
| December 31, 2019 | 30.94M |
| September 30, 2019 | 57.98M |
| June 30, 2019 | 32.87M |
| March 31, 2019 | 32.38M |
| December 31, 2018 | 52.28M |
| September 30, 2018 | 33.40M |
| June 30, 2018 | 38.70M |
| March 31, 2018 | 35.02M |
| December 31, 2017 | 26.00M |
| September 30, 2017 | 27.15M |
| June 30, 2017 | 26.71M |
| March 31, 2017 | 22.68M |
| December 31, 2016 | 22.28M |
| September 30, 2016 | 21.80M |
| June 30, 2016 | 13.53M |
| March 31, 2016 | 11.62M |
| December 31, 2015 | 15.25M |
| September 30, 2015 | 11.57M |
| June 30, 2015 | 11.26M |
| March 31, 2015 | 9.617M |
| December 31, 2014 | 15.14M |
| September 30, 2014 | 13.69M |
| June 30, 2014 | 6.848M |
| March 31, 2014 | 4.410M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Krystal Biotech, Inc. | 13.16M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |
| BioMarin Pharmaceutical, Inc. | 206.95M |
| Cytokinetics, Inc. | 94.18M |
| Exelixis, Inc. | 211.99M |